Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops

Addiction Biology

Volumn 10, Issue 2, 2005, Pages 171-180

  Pijlman, Femke T A ^a   Rigter, S M ^a   Hoek, J ^b   Goldschmidt, H M J ^b   Niesink, R J M ^a  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^b DeltaLab   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; TETRAHYDROCANNABINOL;

ARTICLE; CANNABIS ADDICTION; COFFEE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABUSE; DRUG ABUSE PATTERN; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MARKETING; MEDICAL LIABILITY; NETHERLANDS; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

CANNABIS; CHROMATOGRAPHY, GAS; COFFEE; HALLUCINOGENS; HUMANS; NETHERLANDS; RESTAURANTS; TETRAHYDROCANNABINOL;

EID: 22144447474     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556210500123217     Document Type: Article

References (35)

1. Adams R, Baker B, Wearn R (1940a) Structure of cannabinol III: synthesis of cannaciona, 1-hydroxy-3-n-amyl-6,6,9-trimenthyl-6-dibenzopyran. J Am Chem Soc 62:2204-2207.
2. Adams R, Hunt M, Clark J (1940b) Structure of cannabidiol, a product isolated for the marihuana extrace of Minnesota wild hemp. J Am Chem Soc 62:196-200.
3. Ashton CH (2001) Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 178:101-106.
4. Bachs L, Morland H (2001) Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 124:200-203.
5. Collins L (1999) Hollands half-baked drug experiment. Foreign Affairs Magazine 78:82-98.
6. El Sohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF III (2000) Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 45:24-30.
7. Gaoni R, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647.
8. Giroud G (2002) Analysis of cannabinoids in hemp plants. Chimia 56:80-83.
9. Grinspoon L, Bakalar JB (1997) Marihuana, The Forbidden Medicine. New Haven, CT: Yale University Press.
10. Grotenhermen F (2004) Pharmacology of cannabinoids. Neuro Endocrinol Lett 25:14-23.
11. Hall W, Solowij N (1998) Adverse effects of cannabis. Lancet 352:1611-1616.
12. Hall W, Swift W (2000) The THC content of cannabis in Australia: evidence and implications. Aust NZJ Public Health 24:503-508.
13. Jaeger W, Benet LZ, Bornheim LM (1996) Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26:275-284.
14. Kaa E (1989) Cannabis plants illicitly grown in Jutland (Denmark). Z Rechtsmed 102:367-375.
15. King J (2001) The Cannabible. Berkeley, CA: Ten Speed Press.
16. King LA, Carpenties C, Griffiths P (2004) An overview of cannabis potency in Europe. EMCDDA, European Publications Office.
17. Korf DJ, Biemond R, Jellema R (1994) Cannabis-Monsters UvA. In: Prijs en kwaliteit van illegale drugs in Amsterdam. Korf, DJ, Biemond R, Jellema R, eds, pp. 9-16. Amsterdam: Criminologisch Instituut Bonger.
18. Korf DJ, Wouter M, Benschop A, v. Ginkel P (2004) Sterke Wiet. Amsterdam: Rozenberg Publishers.
19. Mikuriya TH, Aldrich MR (1988) Cannabis 1988. Old drug, new dangers. The potency question. J Psychoactive Drugs 20:47-55.
20. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001) Triggering myocardial infarction by marijuana. Circulation 103:2805-2809.
21. Paris M (1997) [Cannabis: a current topic]. Ann Pharm Fr 55:169-173.
22. Paris M, Tran N (1998) [The existence of "Nederwiet", a new fact in the history of cannabis]. Ann Pharm Fr 56:264-267.
23. Passing H, Bablok W (1983) A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 21:709-720.
24. Perry DC (1977) Street drug analysis and drug use trends 1969-1975. Pharm Chem Newsletter 6:1-3.
25. Pitts JE, O'Neil PJ, Leggo KP (1990) Variation in the THC content of illicitly imported Cannabis products -1984-1989. J Pharm Pharmacol 42:817-820;
26. Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D (2003) Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 69:303-310.
27. Poulsen HA, Sutherland GJ (2000) The potency of cannabis in New Zealand from 1976 to 1996. Sci Justice 40:171-176.
28. Raharjo TJ, Verpoorte R (2004) Methods for the analysis of cannabinoids in biological materials: a review. Phytochem Anal 15:79-94.
29. Rosenthal E (2001) The Big Book of Buds. Oakland, CA: Quick American Archives.
30. Ross SA, El Sohly MA (1997) CBN and delta- 9-THC concentration ratio as an indicator of the age of stored marijuana samples. Bulletin on Narcotics XLIX and L: 139-147.
31. Schwartz RH (2002) Marijuana: a decade and a half later, still a crude drug with underappreciated toxicity. Pediatrics 109:284-289.
32. Smit F, Bolier L, Cuijpers P (2004) Cannabis use and the risk of later schizophrenia: a review. Addiction 99: 425-430.
33. Thompson GR, Mason MM, Rosenkrantz H, Braude MC (1973) Chronic oral toxicity of cannabinoids in rats. Toxicol Appl Pharmacol 25:373
34. Veen ND, Selten JP, van d. TI; Feller WG, Hoek HW, Kahn RS (2004) Cannabis use and age at onset of schizophrenia. Am J Psychiatry 161:501-506.
35. Zuardi AW, Finkelfarb E, Bueno OF, Musty RE, Karniol IG (1981) Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol. Arch. Int Pharmacodyn Ther 249:137-146.